| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Klaus Damgaard Jakobsen, Christina Hedegaard Bruhn, Anne-Katrine Pagsberg, Anders Fink-Jensen, Jimmi Nielse. Neurological, Metabolic, and Psychiatric Adverse Events in Children and Adolescents Treated With Aripiprazole. Journal of clinical psychopharmacology. vol 36. issue 5. 2017-04-28. PMID:27504593. |
aripiprazole is a partial dopamine agonist with only minor neurological and psychiatric adverse effects, making it a potential first-line drug for the treatment of psychiatric disorders. |
2017-04-28 |
2023-08-13 |
Not clear |
| Michael De Santis, Jiamei Lian, Xu-Feng Huang, Chao Den. Early Antipsychotic Treatment in Juvenile Rats Elicits Long-Term Alterations to the Dopamine Neurotransmitter System. International journal of molecular sciences. vol 17. issue 11. 2017-04-04. PMID:27879654. |
the current study investigated potential long-term changes to the adult dopamine (da) system following aripiprazole, olanzapine and risperidone treatment in female and male juvenile rats. |
2017-04-04 |
2023-08-13 |
rat |
| Jiamei Lian, Bo Pan, Chao Den. Early antipsychotic exposure affects serotonin and dopamine receptor binding density differently in selected brain loci of male and female juvenile rats. Pharmacological reports : PR. vol 68. issue 5. 2017-03-20. PMID:27428765. |
this study aimed to investigate the effects of aripiprazole, olanzapine and risperidone on the binding of serotonin (5-ht) and dopamine receptors in juvenile rat brain regions that are involved in antipsychotic efficacy. |
2017-03-20 |
2023-08-13 |
rat |
| Karim Selfani, Valérie L Soland, Sylvain Chouinard, Philippe Huo. Movement Disorders Induced by the "Atypical" Antipsychotic Aripiprazole. The neurologist. vol 22. issue 1. 2017-02-27. PMID:28009769. |
aripiprazole is an antipsychotic that acts as a partial agonist at dopamine d2 receptors. |
2017-02-27 |
2023-08-13 |
Not clear |
| Shuhei Suzuki, Masashi Okada, Kenta Kuramoto, Hiroyuki Takeda, Hirotsugu Sakaki, Hikaru Watarai, Tomomi Sanomachi, Shizuka Seino, Takashi Yoshioka, Chifumi Kitanak. Aripiprazole, an Antipsychotic and Partial Dopamine Agonist, Inhibits Cancer Stem Cells and Reverses Chemoresistance. Anticancer research. vol 36. issue 10. 2017-01-27. PMID:27798875. |
aripiprazole, an antipsychotic and partial dopamine agonist, inhibits cancer stem cells and reverses chemoresistance. |
2017-01-27 |
2023-08-13 |
Not clear |
| Shuhei Suzuki, Masashi Okada, Kenta Kuramoto, Hiroyuki Takeda, Hirotsugu Sakaki, Hikaru Watarai, Tomomi Sanomachi, Shizuka Seino, Takashi Yoshioka, Chifumi Kitanak. Aripiprazole, an Antipsychotic and Partial Dopamine Agonist, Inhibits Cancer Stem Cells and Reverses Chemoresistance. Anticancer research. vol 36. issue 10. 2017-01-27. PMID:27798875. |
the anticancer activities of aripiprazole, an antipsychotic drug with partial dopamine agonist activity and an excellent safety profile, remain unknown. |
2017-01-27 |
2023-08-13 |
Not clear |
| Suravi Patr. Tardive Dyskinesia and Covert Dyskinesia with Aripiprazole: A Case Series. Current drug safety. vol 11. issue 1. 2016-12-13. PMID:26391425. |
aripiprazole, a dopamine stabilizing atypical antipsychotic is used in treatment of tardive dyskinesia caused by other neuroleptics. |
2016-12-13 |
2023-08-13 |
Not clear |
| David J G Watson, Madeleine V King, Istvan Gyertyán, Béla Kiss, Nika Adham, Kevin C F Fon. The dopamine D₃-preferring D₂/D₃ dopamine receptor partial agonist, cariprazine, reverses behavioural changes in a rat neurodevelopmental model for schizophrenia. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 26. issue 2. 2016-12-13. PMID:26723167. |
results suggest that in the behavioural tests investigated cariprazine is at least as effective as aripiprazole and in some paradigms it showed additional beneficial features further supporting the advantage of combined dopamine d3/d2 receptor targeting. |
2016-12-13 |
2023-08-13 |
rat |
| Anna Murphy, Serdar Dursun, Shane McKie, Rebecca Elliott, John Francis William Deaki. An investigation into aripiprazole's partial D₂ agonist effects within the dorsolateral prefrontal cortex during working memory in healthy volunteers. Psychopharmacology. vol 233. issue 8. 2016-12-13. PMID:26900078. |
aripiprazole is a d2 receptor partial agonist hypothesised to enhance pfc dopamine functioning, possibly improving working memory. |
2016-12-13 |
2023-08-13 |
human |
| Bo Pan, Xu-Feng Huang, Chao Den. Aripiprazole and Haloperidol Activate GSK3β-Dependent Signalling Pathway Differentially in Various Brain Regions of Rats. International journal of molecular sciences. vol 17. issue 4. 2016-12-13. PMID:27043526. |
aripiprazole, a dopamine d₂ receptor (d₂r) partial agonist, possesses a unique clinical profile. |
2016-12-13 |
2023-08-13 |
rat |
| Luara A Batista, Thércia G Viana, Vívian T Silveira, Daniele C Aguiar, Fabrício A Moreir. Effects of aripiprazole on caffeine-induced hyperlocomotion and neural activation in the striatum. Naunyn-Schmiedeberg's archives of pharmacology. vol 389. issue 1. 2016-10-07. PMID:26319049. |
aripiprazole is an antipsychotic that acts as a partial agonist at dopamine d2 receptors. |
2016-10-07 |
2023-08-13 |
mouse |
| Ingeborg Bolstad, Ole A Andreassen, Inge Groote, Andres Server, Ivar Sjaastad, Shitij Kapur, Jimmy Jense. Effects of haloperidol and aripiprazole on the human mesolimbic motivational system: A pharmacological fMRI study. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 25. issue 12. 2016-10-05. PMID:26476705. |
the atypical antipsychotic drug aripiprazole is a partial dopamine (da) d2 receptor agonist, which differentiates it from most other antipsychotics. |
2016-10-05 |
2023-08-13 |
human |
| Marie Grall-Bronnec, Anne Sauvaget, Fanny Perrouin, Juliette Leboucher, François Etcheverrigaray, Gaëlle Challet-Bouju, Louise Gaboriau, Pascal Derkinderen, Pascale Jolliet, Caroline Victorri-Vignea. Pathological Gambling Associated With Aripiprazole or Dopamine Replacement Therapy: Do Patients Share the Same Features? A Review. Journal of clinical psychopharmacology. vol 36. issue 1. 2016-09-26. PMID:26658263. |
pathological gambling associated with aripiprazole or dopamine replacement therapy: do patients share the same features? |
2016-09-26 |
2023-08-13 |
Not clear |
| Serena Deiana, Akihito Watanabe, Yuki Yamasaki, Naoki Amada, Tetsuro Kikuchi, Colin Stott, Gernot Riede. MK-801-induced deficits in social recognition in rats: reversal by aripiprazole, but not olanzapine, risperidone, or cannabidiol. Behavioural pharmacology. vol 26. issue 8 Spec No. 2016-08-22. PMID:26287433. |
collectively, the combined activity of aripiprazole on dopamine d2 and serotonin 5ht1a receptors appears to provide a significant advantage over risperidone and olanzapine with respect to the rescue of cognitive deficits reminiscent of schizophrenia. |
2016-08-22 |
2023-08-13 |
human |
| Ana F Almeida-Santos, Renata C M Ferreira, Igor D Duarte, Daniele C Aguiar, Thiago R L Romero, Fabricio A Moreir. The antipsychotic aripiprazole induces antinociceptive effects: Possible role of peripheral dopamine D2 and serotonin 5-HT1A receptors. European journal of pharmacology. vol 765. 2016-08-12. PMID:26325094. |
the antipsychotic aripiprazole induces antinociceptive effects: possible role of peripheral dopamine d2 and serotonin 5-ht1a receptors. |
2016-08-12 |
2023-08-13 |
mouse |
| Ana F Almeida-Santos, Renata C M Ferreira, Igor D Duarte, Daniele C Aguiar, Thiago R L Romero, Fabricio A Moreir. The antipsychotic aripiprazole induces antinociceptive effects: Possible role of peripheral dopamine D2 and serotonin 5-HT1A receptors. European journal of pharmacology. vol 765. 2016-08-12. PMID:26325094. |
aripiprazole is an antipsychotic that acts by multiple mechanisms, including partial agonism at dopamine d2 and serotonin 5-ht1a receptors. |
2016-08-12 |
2023-08-13 |
mouse |
| Ana F Almeida-Santos, Renata C M Ferreira, Igor D Duarte, Daniele C Aguiar, Thiago R L Romero, Fabricio A Moreir. The antipsychotic aripiprazole induces antinociceptive effects: Possible role of peripheral dopamine D2 and serotonin 5-HT1A receptors. European journal of pharmacology. vol 765. 2016-08-12. PMID:26325094. |
the peripheral action of aripiprazole (100 µg/paw) was reversed by haloperidol (0.1-10 µg/paw), suggesting the activation of dopamine receptors as a possible mechanism. |
2016-08-12 |
2023-08-13 |
mouse |
| Andrea de Bartolomeis, Carmine Tomasetti, Felice Iasevol. Update on the Mechanism of Action of Aripiprazole: Translational Insights into Antipsychotic Strategies Beyond Dopamine Receptor Antagonism. CNS drugs. vol 29. issue 9. 2016-07-15. PMID:26346901. |
this review aims to recapitulate the main neurobiological effects of aripiprazole and discuss the potential implications for upcoming improvements in schizophrenia therapy based on dopamine modulation beyond d2r antagonism. |
2016-07-15 |
2023-08-13 |
Not clear |
| Claire Chevreuil, Elisabeth Polard, Eric Lemonnier, Paul Guillemot, Danièle Bentué-Ferre. [Not Available]. Therapie. vol 66. issue 2. 2016-07-12. PMID:27393647. |
its mechanism of action is different as aripiprazole is a partial dopamine d2 and serotonin 5-ht1a receptor agonist and 5-ht2a receptor antagonist. |
2016-07-12 |
2023-08-13 |
Not clear |
| Sam Padamadan Josep. Aripiprazole-induced Hyperprolactinemia in a Young Female with Delusional Disorder. Indian journal of psychological medicine. vol 38. issue 3. 2016-06-23. PMID:27335526. |
aripiprazole being a partial agonist has a lower intrinsic activity at the d2 receptor than dopamine, allowing it to act as both, a functional agonist and antagonist, depending on the surrounding levels of dopamine. |
2016-06-23 |
2023-08-13 |
Not clear |